PHAS - Liquidia slumps as United MannKind get FDA nod for rival therapy

North Carolina-based pharma company Liquidia Corporation (NASDAQ:LQDA) lost sharply on Monday after the FDA announced the approval of a rival lung disease therapy developed by United Therapeutics (UTHR) and its partner MannKind (MNKD). Rejecting a Citizen Petition filed against its marketing application, the FDA greenlighted Tyvaso DPI,  an inhaler drug combination to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease. Last year, Liquidia (LQDA) obtained the tentative FDA approval for its experimental drug Yutrepia, an inhalational dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability. Other developers focused on PAH therapies include PhaseBio (PHAS) which ended the mid-stage trial for its asset last year amid COVID impact and Acceleron Pharma. When Merck (MRK) aquired Acceleron last year, the company was advancing a Phase 3 trial for its PAH candidate Sotatercept as an add-on to current standard of

For further details see:

Liquidia slumps as United, MannKind get FDA nod for rival therapy